HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

NCT07215468 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV -1 Infection

Interventions

DRUG: TMB-365
DRUG: TMB-380
DRUG: Baseline ART

Sponsor

TaiMed Biologics Inc.